Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Jan A. Burger, Alessandra Tedeschi, Paul M. Barr et al. · New England Journal of Medicine · 2015 · 1.5K citations · Full text

Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

Zhengying Pan, Heleen Scheerens, Shyr‐Jiann Li et al. · ChemMedChem · 2006 · 669 citations

Rheumatoid Disorder, Molecular Pharmacology, Medicinal Chemistry +14

Harmonization of strategies for the validation of quantitative analytical procedures

P. Hubert, J.-J. Nguyen-Huu, Bruno Boulanger et al. · Journal of Pharmaceutical and Biomedical Analysis · 2007 · 539 citations

Reliability, Method Validation, Methodological Development +11

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Martin Dreyling, Wojciech Jurczak, Mats Jerkeman et al. · The Lancet · 2015 · 456 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Refractory Mantle-cell Lymphoma +7